检索结果-南通市图书馆

Regulation of plasma erythropoietin in chronic liver disease

World Journal of Gastroenterology 2004年第19期10卷 2922-2923页

作者： Frank Tacke tom luedde Michael P.Manns Christian Trautwein Department of Gastroenterology Hepatology and EndocrinologyHannover Medical School 30625 HannoverGermany Department of Gastroenterology Hepatology and EndocrinologyHannover Medical School 30625 HannoverGermany M.D.Professor of Medicine

In a May-issue of the World Journal of Gastroenterology, there is a very interesting study by Bruno et al. on erythropoietin (EPO) levels in patients with chronic liver disease. We have very recently reported a similar, but much larger study by Tacke et al. on the role of EPO in chronic liver disease. By comparing Bruno's results with our patient cohort and applying their

关键词： Aged Biological Markers Erythropoietin Female Hepatitis, Chronic Humans

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Long-term survival of a HCC-patient with severe liver dysfunction treated with sorafenib

引用

World Journal of Hepatology 2010年第6期2卷 239-242页

作者： Christoph Roderburg Jhenee Bubenzer Michael Spannbauer Nicole do O Andreas Mahnken tom luedde Christian Trautwein Jens JW Tischendorf Department of Medicine Ⅲ University of Aachen (RWTH) Department of Radiology University of Aachen (RWTH)

Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver. Prognosis and treatment options are stage dependent. In general, prognosis of patients with unresectable HCC is poor, especially for those patients with impaired liver function. Whereas treatment with the novel molecular tyrosine kinase inhibitor sorafenib (Nexavar) was shown to result in prolonged survival in patients with preserved liver function, its' possible application in HCC-patients with strongly impaired liver function has not been clearly assessed. Here, we report on a 47-year-old male patient who presented with Child-Pugh class C liver cirrhosis and multifocal, non-resectable HCC. The patient was treated for 27 mo with Sorafenib, which was not associated with major drug-related side effects. During treatment, a reduction in tumour size of 24% was achieved, as assessed by regular CT scan. Moreover,within the 27 mo interval of stable tumour disease, liver function improved from Child-Pugh class C to class A.

关键词： Hepatocellular carcinoma Sorafenib Liver cirrhosis Child-Pugh score Long-term survival

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：